bsignificant (p ≤ 0.05) as compared to E2-implanted PD-L1-/- B cell-recipient group
csignificant (p ≤ 0.05) as compared to E2-implanted no cell transfer μMT-/- recipient group
*Statistical evaluation of EAE disease course for Control and E2-implanted recipient μMT-/- mice, including the Cumulative Disease Index (CDI), through day 26 postimmunization for the 2-3 experiments (n=3-5 mice/group/experiment). The daily disease scores from pooled data and corresponding CDI data from each of the independent experiments (mean ± SEM) are presented. Additional information for the experiments is shown in Figure 6.
|Table 2: Clinical course of EAE in B-cell-recipient μMT-/- mice*.|